Otezla Archives - Journal for Clinical Studies

Regional News

Bristol Myers Squibb’s next-gen autoimmune med starts high-stakes FDA review amid classwide JAK scrutiny

After the FDA slapped an updated safety warning on marketed oral JAK inhibitors for inflammatory diseases, market watchers have started worrying about other candidate...

1 December 2021 Regional News Autoimmune Diseases | Bristol Myers Squibb

Continue Reading →

Regional News

Amgen’s Otezla, Repatha and biosimilars put on notice, with challenging years ahead

Some of Amgen’s key businesses are drawing concerns as competition looms. Amgen’s 2022 sales could be about $26.3 billion, or $700 million lower than industry watche...

24 November 2021 Regional News Aimovig | Amgen Repatha

Continue Reading →

Regional News

Amgen scores Otezla patent win, protecting its blockbuster from Sandoz and Zydus generics until 2028

When Amgen bought marketing rights to psoriasis pill Otezla for $13.4 billion two years ago, the company was likely counting on not having to compete against early ge...

22 September 2021 Regional News Amgen | Otezla

Continue Reading →

Derisking FIH Integrated Strategies

Current Edition

Bristol Myers Squibb’s next-gen autoimmune med starts high-stakes FDA review amid classwide JAK scrutiny

Amgen’s Otezla, Repatha and biosimilars put on notice, with challenging years ahead

Amgen scores Otezla patent win, protecting its blockbuster from Sandoz and Zydus generics until 2028

Journal for Clinical Studies